23 cents The imperative for Phase II was to treat a small but statistically-significant number of Patients (say 10) in Canada asap.If these had shown a CR at 6 months and the second treatment then proved safe it was game over and TLT had won. Such Clinical success would have made US commercial approval little more than a formality and value would have come into the Company in short order.
As it stands they languish at 23 cents so why didn`t this happen?It seems less likely that people have suddenly stopped developing refractory NMIBC and more probably related to the process of allocation from the available pool of triallists. Those referring to perceived conflicts of interest re. Prof.Kamat might look closer to home.The alarm bells rang during Prof.Jewett`s AGM Presentation - from memory something like ‘we will be jockeying for position among competing Trials’ which was subsequently translated to mean ‘ we will only have treated 7 in Canada with long delays between each by May 2020 and we won`t have any meaningful data ’til the end of that year’.
You`d think that pre-eminent Urologists of the status of Profs.Jewett and Wilson would have the autonomy to refer such patients as they wished to any given Trial but it doesn`t look that way. Prof.Jewett`s expectation management seemed based on dictat - that he`d already been told how it was going to be for TLT and that it wasn`t going to be good so we got the excuses in advance.
There can`t be many in Canada at the level above them and that is where medicine meets money and politics.